Skip to main content
. 2020 Oct 13;3(10):e2020312. doi: 10.1001/jamanetworkopen.2020.20312

Figure 3. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors (CDK4/6) Plus Endocrine Therapy (ET) vs ET Alone With the Objective Response Rate Among Women With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer.

Figure 3.

The Mantel-Haenszel method and a fixed-effect model were used in the analysis. The size of the data markers (squares) corresponds to the weight of the study in the meta-analysis. F indicates fulvestrant; OR, odds ratio; and NSAI, nonsteroidal aromatase inhibitor.